You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T315I mutation

Showing 1 - 25 of 4,810
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

3L+ Therapies Among Chronic Myeloid Leukemia and Those With

Completed
  • Chronic Myeloid Leukemia
    • East Hanover, New Jersey
      Novartis Investigative Site
    Nov 11, 2022

    Needs of 3L+ CP-CML and With T315I-mutated CML Patients

    Completed
    • Chronic Myeloid Leukemia
    • 3L Therapy
    • T315I
    • Lyon, France
      Novartis Investigative Site
    Nov 9, 2022

    Chronic Myeloid Leukemia Trial (Asciminib)

    Available
    • Chronic Myeloid Leukemia
    • (no location specified)
    Jan 17, 2023

    Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in China (Ponatinib)

    Recruiting
    • Chronic Myeloid Leukemia
    • Acute Lymphoblastic Leukemia
    • Hefei, Anhui, China
    • +13 more
    Aug 11, 2020

    Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

    Completed
    Has Results
    • Chronic Myeloid Leukemia
    • Omacetaxine mepesuccinate
    • Los Angeles, California
    • +31 more
    Nov 11, 2021

    Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive Trial in Moscow, St. Petersburg (PF-114)

    Unknown status
    • Chronic Myeloid Leukemia
    • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    • Moscow, Russian Federation
    • +2 more
    Feb 13, 2020

    Chronic Myelogenous Leukemia - Chronic Phase Trial (asciminib)

    Recruiting
    • Chronic Myelogenous Leukemia - Chronic Phase
    • Birmingham, Alabama
    • +25 more
    Jan 10, 2023

    Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL),

    Recruiting
    • Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
    • +2 more
    • Phoenix, Arizona
    • +69 more
    Aug 23, 2022

    Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

    Not yet recruiting
    • Metastatic Colorectal Adenocarcinoma
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Sep 12, 2023

    Outcomes in Chronic Myeloid Leukaemia

    Completed
    • Chronic Myeloid Leukaemia
      • York, United Kingdom
        Haematological Malignancy Research Network
      Jun 7, 2023

      Advanced Solid Tumor Trial in Beijing (YK0901 cells)

      Not yet recruiting
      • Advanced Solid Tumor
      • YK0901 cells
      • Beijing, China
        Department of GI Oncology, Peking University Cancer Hospital
      Jun 27, 2023

      NSCLC Trial in Beijing, Nanjing, Suzhou (BPI-7711 Capsule)

      Completed
      • Non-small Cell Lung Cancer
      • BPI-7711 Capsule
      • Beijing, Beijing, China
      • +3 more
      May 13, 2022

      Trial (Olverembatinib)

      Available
        • (no location specified)
        Nov 10, 2022

        HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

        Recruiting
        • HER2-positive Breast Cancer
        • +17 more
        • ALX148
        • Fam-Trastuzumab Deruxtecan-Nxki
        • Chicago, Illinois
        • +1 more
        May 19, 2023

        Real-World Usage of Asciminib Among Chronic Myeloid Leukemia in

        Completed
        • Chronic Myeloid Leukemia
          • East Hanover, New Jersey
            Novartis
          Nov 20, 2023

          Patisiran in Polyneuropathy of ATTRv Amyloidosis WithV122I or

          Active, not recruiting
          • Hereditary Transthyretin-mediated (ATTRv) Amyloidosis
          • Polyneuropathy
          • Los Angeles, California
          • +26 more
          Mar 4, 2022

          CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))

          Recruiting
          • CML, Chronic Phase
          • CML, Accelerated Phase
          • HS-10382(Part 1: Dose escalation)
          • HS-10382(Part 2: Dose expansion)
          • Wuhan, Hubei, China
            Union Hospital affiliated to Tongji Medical College of Huazhong
          Jan 12, 2023

          Osimertinib in Advanced Non-Small Cell Lung Cancer EGFR-T790M

          Completed
          • Non Small Cell Lung Cancer
          • Oviedo, Asturias, Spain
          • +30 more
          Jun 1, 2022

          Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia Trial in Worldwide (Ponatinib)

          Completed
          Has Results
          • Chronic Myeloid Leukemia
          • Ph+ Acute Lymphoblastic Leukemia
          • St Leonards, New South Wales, Australia
          • +41 more
          Jan 18, 2021

          HLA Typing and Tumor Neoantigen Identification forPhase I/II

          Recruiting
          • Ovarian Cancer
          • +5 more
            • Houston, Texas
              MD Anderson Cancer Center
            Jul 27, 2022

            Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer Trial in Worldwide (AZD5363 when combined with

            Completed
            Has Results
            • Advanced or Metastatic Breast Cancer
            • ER+ve Advanced or Metastatic Breast Cancer
            • AZD5363 when combined with weekly paclitaxel.
            • +2 more
            • Plovdiv, Bulgaria
            • +40 more
            Dec 23, 2022

            Non Small Cell Lung Cancer Trial in China (XZP-5809-TT1 Tablet)

            Recruiting
            • Non Small Cell Lung Cancer
            • XZP-5809-TT1 Tablet
            • Beijing, Beijing, China
            • +4 more
            Mar 17, 2021

            Unraveling KAdcyla Resistance In Human Epidermal Growth Factor

            Completed
            • Advanced Breast Cancer
              • Sevilla, Andalucía, Spain
              • +9 more
              Jan 12, 2023

              Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Canada, United States (Enasidenib, Enasidenib

              Recruiting
              • Recurrent Acute Myeloid Leukemia
              • Refractory Acute Myeloid Leukemia
              • Birmingham, Alabama
              • +17 more
              Jun 21, 2021

              Metastatic Melanoma Trial in Worldwide (LGX818, MEK162, Nivolumab)

              Active, not recruiting
              • Metastatic Melanoma
              • Salzburg, AT, Austria
              • +29 more
              Feb 23, 2022